Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,893 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05127590 | RBN-2397 in Combination With Pembrolizumab in Patients With SCCL | unknown | Phase 1 / Phase 2 | 50 | Ribon Therapeutics, Inc.INDUSTRY | 4 | Jul 3, 2023 | clinicaltrials |
| NCT05925738 | Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung Cancer | unknown | — | 1,500 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT05925751 | Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung Cancer | unknown | — | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04227444 | Preoperative Evaluation of Pulmonary Vascular Anatomy by Holograms(Holo-lungs) | unknown | — | 50 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05912465 | Predicting Lung Cancer-Associated Cachexia With PET Imaging(LUCAPET) | unknown | N/A | 150 | Medical University of ViennaOTHER | 3 | Jun 27, 2023 | clinicaltrials |
| NCT05921474 | Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors(SABR-DETECT) | unknown | — | 100 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05919641 | LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT(LIVELUNG) | unknown | — | 130 | Odense University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT02786589 | Plasmodium Immunotherapy for Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | State Key Laboratory of Respiratory DiseaseOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05203276 | Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC | unknown | Phase 2 | 40 | The First People's Hospital of LianyungangOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05910034 | Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC | unknown | Phase 2 | 132 | Fudan UniversityOTHER | 0 | Jun 18, 2023 | clinicaltrials |
| NCT05910112 | Prospective Data Collection on Clinical, Radiological and Patient Reported Outcomes After Pleural Intervention(PROSPECT) | unknown | — | 2,000 | University of OxfordOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05489731 | VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer(VIC-1911) | unknown | Phase 1 | 72 | Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.OTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05906329 | Low-dose Radiotherapy Combined With Conventional Fractionated Radiotherapy in Lung Cancer After Immunotherapy Resistance(FL002) | unknown | N/A | 20 | Qianfoshan HospitalOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT04726358 | ProCaLung: Project on Cancer of the Lung(ProCaLung) | unknown | — | 1,000 | Jules Bordet InstituteOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT05899270 | 3D-printed Reconstruction Automated Matching System Predicts Size of Double-lumen Tube: a Prospective Double-blinded Randomized Controlled Trial | unknown | N/A | 200 | Sichuan Cancer Hospital and Research InstituteOTHER | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05900219 | Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study | unknown | Phase 2 | 75 | Shanghai Kechow Pharma, Inc.INDUSTRY | 0 | Jun 12, 2023 | clinicaltrials |
| NCT05896059 | A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC | unknown | Phase 2 | 21 | Zhejiang Cancer HospitalOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05527808 | A Single-arm Exploratory Study of Neoadjuvant Therapy | unknown | N/A | 28 | Jun LiuOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05780307 | IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors | unknown | Phase 1 | 48 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT05890820 | The Effect of Nutritional Risk Parameters on Postoperative Pulmonary Complications in Geriatric Thoracic Surgery Cases | unknown | — | 100 | Ankara Ataturk Sanatorium Training and Research HospitalOTHER_GOV | 1 | Jun 6, 2023 | clinicaltrials |
| NCT05760170 | Determining Clinical Trial Experiences of Lung Cancer Patients | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Jun 5, 2023 | clinicaltrials |
| NCT03568097 | Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer(PAVE) | unknown | Phase 2 | 55 | Hellenic Cooperative Oncology GroupOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05885815 | Application of SERS Technology in Clinical Diagnosis and Prognosis of Lung Cancer Immunotherapy | unknown | — | 500 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jun 2, 2023 | clinicaltrials |
| NCT05885984 | Acceptance and Commitment Therapy on Fatigue Interference in Patients With Advanced Lung Cancer and Caregiver Burden (ACT) | unknown | N/A | 80 | Chinese University of Hong KongOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05886075 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors | unknown | Early Phase 1 | 24 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | Jun 2, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05498389 | EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer | unknown | Phase 1 / Phase 2 | 115 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Jun 1, 2023 | clinicaltrials |
| NCT03797391 | A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 186 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | May 31, 2023 | clinicaltrials |
| NCT04409444 | Manchester Lung Health Study(qUEST) | unknown | — | 9,730 | Manchester University NHS Foundation TrustOTHER_GOV | 1 | May 31, 2023 | clinicaltrials |
| NCT05306652 | Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment(EXcellenT) | unknown | N/A | 40 | AUSL Romagna RiminiOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05882630 | Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 39 | Fujian Cancer HospitalOTHER_GOV | 1 | May 31, 2023 | clinicaltrials |
| NCT04489992 | Experiment on the Use of Innovative Computer Vision Technologies for Analysis of Medical Images in the Moscow Healthcare System | unknown | — | 133,000 | Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care DepartmentOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT02724696 | French National Observatory of Patients With Thymic Epithelial Tumor(RYTHMIC) | unknown | — | 3,262 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT05872126 | Video Assisted Thoracoscopic Surgery (VATS) - Surgical Pleurodesis vs Tube Drainage in Management of Malignant Pleural Effusion (MPE) | unknown | N/A | 60 | Assiut UniversityOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT05873790 | Minimal Residual Disease Dynamic Monitoring in First-Line Serplulimab Plus Chemotherapy in Treatment of Extensive Small Cell Lung Cancer: An Observational Study | unknown | — | 30 | The First Hospital of Jilin UniversityOTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT03094884 | Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer | unknown | Phase 1 | 40 | Fox Chase Cancer CenterOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT04676815 | Narrow Band Imaging (NBI) Under Electronic Bronchoscope in Lung Cancer | unknown | — | 200 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT04580498 | A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC | unknown | Phase 2 | 107 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT05865730 | A Study of Oncobax®-AK in Patients With Advanced Solid Tumors | unknown | Phase 2 | 122 | EverImmuneINDUSTRY | 2 | May 19, 2023 | clinicaltrials |
| NCT05859373 | To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer. | unknown | Phase 1 / Phase 2 | 78 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT05860374 | A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors | unknown | Early Phase 1 | 20 | Shanghai Yunying Medical TechnologyINDUSTRY | 1 | May 16, 2023 | clinicaltrials |
| NCT04940637 | UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC(UNITO-001) | unknown | Phase 2 | 70 | University of Turin, ItalyOTHER | 1 | May 12, 2023 | clinicaltrials |
| NCT05854030 | Serum Exosomal miRNA Predicting the Therapeutic Efficiency in Lung Squamous Carcinoma | unknown | — | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT04202809 | Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.(ESPADURVA) | unknown | Phase 2 | 90 | University Hospital, EssenOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05783024 | Advanced Data-Aided Medicine Part Lung Cancer(ADAMpartlung) | unknown | — | 500 | AZ DeltaOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05157776 | A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations | unknown | Phase 3 | 72 | Tongji UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05354882 | Interventional Study on DEterminants and Factors of Physical ACtivity After Treatments in Oncology(DEFACTO2) | unknown | N/A | 150 | Université Sorbonne Paris NordOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT05850702 | Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine | unknown | Phase 4 | 92 | RenJi HospitalOTHER | 0 | May 9, 2023 | clinicaltrials |
| NCT05847764 | Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | unknown | Phase 2 | 95 | Sun Yat-sen UniversityOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT03217669 | Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy | unknown | Phase 1 | 15 | Chao HuangOTHER | 1 | May 3, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jul 3, 2023source: clinicaltrials